Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.17 USD
+0.04 (3.54%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.15 -0.02 (-1.71%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 41 - 60 ( 274 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q1: All Eyes on Cohort 3 & 4 Data from Ph1/2a OASIS Trial of CLS-AX/wAMD in Q4
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
ARVO, the Global Ophthalmology Meeting Begins on Sunday, May 1st in Denver
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE Commercially Launched in the U.S.; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Update - Progress Highlights Market Inefficiencies & More to Come
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
OASIS Expanded to Include Cohort 4, Positive Partner Program Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Angio 2022: Keeping Safety First While Advancing Towards Extended Duration
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Cash Balance and 2022 Catalysts For Our Biotech Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
BEST IDEAS LIST - Removing SAIL and MTTR
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Positive Data from Cohort 2 of Wet AMD trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
CLS-AX''s Safety Supports Continued Dose-Escalation in Wet AMD
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
CLS-AX Heating Up in Time for Winter with Clean Safety & Dose Response
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
We are removing OPEN and WIX from the Best Ideas List due to our investment price discipline.
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department